Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Norway
  4. Oslo Bors
  5. EXACT Therapeutics AS
  6. News
  7. Summary
    EXTX   NO0010852213

EXACT THERAPEUTICS AS

(EXTX)
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

EXACT Therapeutics : Share capital increase registered

06/30/2021 | 05:19am EDT
Oslo, 30 June 2021 - Reference is made to the announcement by EXACT Therapeutics
AS ('EXACT-Tx' or the 'Company') on 7 June 2021 regarding the issuance of 24,427
new shares in the Company, for the purpose of issuing shares under the Company's
restricted stock unit (RSU) program to its Board members.
 
The share capital increase pertaining to the issuance of the new shares has now
been registered with the Norwegian Register of Business Enterprises. The
Company's new registered share capital is NOK 119,968.668 divided into
29,992,167 shares, each with a nominal value of NOK 0.004.
 
DISCLOSURE REGULATION
This information is subject to the disclosure requirements pursuant to Section
5-12 of the Norwegian Securities Trading Act.

About EXACT-Tx
EXACT-Tx is a clinical stage Norwegian biotech company developing a technology
platform for targeted therapeutic enhancement - Acoustic Cluster Therapy (ACT®).
ACT® sonoporation is a unique approach to ultrasound-mediated, targeted drug
enhancement - with the potential to significantly amplify the clinical utility
of a wide range of therapeutic agents across a multitude of indications
including within oncology (chemotherapy, immunotherapy), infectious diseases,
and neurological conditions. www.exact-tx.com

Click here for more information

© Oslo Bors ASA, source Oslo Stock Exchange

All news about EXACT THERAPEUTICS AS
10/19EXACT THERAPEUTICS : Announces changes to the management team
AQ
10/19EXACT Therapeutics AS Announces Executive Changes
CI
10/19EXACT Therapeutics AS Announces Changes to the Management Team
CI
09/22EXACT THERAPEUTICS : announces interim results for first half 2021
AQ
09/22Exact Therapeutics as Reports Earnings Results for the Half Year Ended June 30, 2021
CI
06/30EXACT THERAPEUTICS : Share capital increase registered
AQ
06/07EXACT THERAPEUTICS AS : Primary insider notices
AQ
06/07EXACT THERAPEUTICS AS : Share Capital Increase
AQ
06/01EXACT THERAPEUTICS AS : Minutes of Annual General Meeting 2021
AQ
05/28EXACT THERAPEUTICS : Announces clinical trial update
AQ
More news
Financials
Sales 2020 - - -
Net income 2020 -33,1 M -3,94 M -3,94 M
Net cash 2020 160 M 19,0 M 19,0 M
P/E ratio 2020 -26,7x
Yield 2020 -
Capitalization 539 M 64,1 M 64,2 M
EV / Sales 2019 -
EV / Sales 2020 -
Nbr of Employees 8
Free-Float 33,9%
Chart EXACT THERAPEUTICS AS
Duration : Period :
EXACT Therapeutics AS Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Dominic Michael Moreland Chief Executive & Financial Officer
Masha Paule Nathalie Str°mme Executive Chairman
Andrew John Healey Chief Scientific Officer
Spiros Kotopoulis Chief Technology Officer
Hilary McElwaine-Johnn Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
EXACT THERAPEUTICS AS-38.98%65
MODERNA, INC.230.95%139 557
LONZA GROUP AG32.63%60 898
IQVIA HOLDINGS INC.42.93%48 923
SEAGEN INC.1.46%32 330
CELLTRION, INC.-38.02%26 036